KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Quest Diagnostics (DGX) EPS (Weighted Average and Diluted) (2016 - 2026)

Quest Diagnostics' EPS (Weighted Average and Diluted) history spans 18 years, with the latest figure at $2.24 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 15.46% to $2.24 in Q1 2026 year-over-year; TTM through Mar 2026 was $9.05, a 14.41% increase, with the full-year FY2025 number at $8.75, up 13.78% from a year prior.
  • EPS (Weighted Average and Diluted) hit $2.24 in Q1 2026 for Quest Diagnostics, up from $2.18 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for DGX hit a ceiling of $2.92 in Q1 2022 and a floor of $0.92 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $2.01 across 5 years, with a median of $1.99 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 70.7% in 2022 and later soared 84.78% in 2023.
  • Tracing DGX's EPS (Weighted Average and Diluted) over 5 years: stood at $0.92 in 2022, then skyrocketed by 84.78% to $1.7 in 2023, then grew by 14.71% to $1.95 in 2024, then increased by 11.79% to $2.18 in 2025, then grew by 2.75% to $2.24 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for DGX at $2.24 in Q1 2026, $2.18 in Q4 2025, and $2.16 in Q3 2025.